01重点学术场次Priority Sessions14 场
本专题的重点场次包含 Hot Line、LBCS、New ESC Guidelines、Ask the Trialists、Guidelines in Practice、Great Debates 等。
指南与标准5 场
New Guidelines
心肌梗死第五次通用定义（ESC/ACC/AHA/WHF）
5th Universal Definition of Myocardial Infarction (ESC, ACC, AHA, and WHF)
Guidelines in Practice
合并显著冠心病的主动脉瓣狭窄
aortic stenosis with significant coronary artery disease
Guidelines in Practice
继发性二尖瓣反流管理
management of secondary mitral regurgitation
心肌病与心包4 场Hot Line 1
Hot Line
HOT LINE 1（全球首发专场）
HOT LINE 1
CARDIO-TTRansform：eplontersen 治疗转甲状腺素蛋白淀粉样心肌病的疗效与安全性
CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy
SINGLE-AF：中危卒中风险房颤的抗凝治疗
SINGLE-AF: Anticoagulation for atrial fibrillation with intermediate stroke risk
POET-II：感染性心内膜炎的个体化疗程抗生素治疗
POET-II: tailored duration antibiotic treatment for infectious endocarditis
ACACIA-HCM：Aficamten 治疗有症状的非梗阻性肥厚型心肌病
ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy
CMR GUIDE：心脏磁共振指导轻中度左室收缩功能障碍患者 ICD 植入管理
CMR GUIDE: cardiac magnetic resonance GUIDEd management of mild-moderate left ventricular systolic dysfunction with an ICD
LBCS
晚期临床科学：肥厚型心肌病
Late-Breaking Clinical Science: hypertrophic cardiomyopathy
aficamten 对有症状非梗阻性肥厚型心肌病患者心脏结构与功能的影响——ACACIA-HCM 试验结果
Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial
MAPLE-HCM：按试验前用药分层，Aficamten 对比美托洛尔单药治疗梗阻性肥厚型心肌病
Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM
超声心动图深度学习模型检测、表型分型与估算肥厚型心肌病左室压差：开发与多国外部验证
Deep Learning Model for Detection, Phenotyping, and Left Ventricular Gradient Estimation in Hypertrophic Cardiomyopathy Using Echocardiography: Development and Multinational External Validation
马瓦卡姆腾治疗梗阻性肥厚型心肌病长达 5 年的安全性与有效性：MAVA-LTE 最终结果
Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE
LBCS
晚期临床科学：心脏淀粉样变
Late-Breaking Clinical Science: cardiac amyloidosis
I124-依伐珠单抗诊断心脏淀粉样变的 3 期临床试验
A Phase 3 Clinical Trial of I124-evuzamitide to Diagnose Cardiac Amyloidosis
CARDIO-TTRansform 试验：接受稳定剂治疗的转甲状腺素蛋白淀粉样心肌病患者中基因沉默药物 eplontersen 的疗效与安全性
Efficacy and safety of transthyretin gene silencer eplontersen in patients with transthyretin amyloid cardiomyopathy receiving stabiliser therapy in the CARDIO-TTRansform trial
转甲状腺素蛋白淀粉样心肌病中按基线氯苯唑酸使用情况分层的 vutrisiran 效应
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy
ATTR-CM 基因沉默疗法的荟萃分析
A Meta-Analysis of Gene Silencer Therapy in ATTR-CM
anselamimab 对轻链型淀粉样变患者心脏结构与功能的影响：CARES 试验
Effect of anselamimab on cardiac structure and function in patients with light chain amyloidosis: The CARES trials
Great Debates
焦点辩论：β 受体阻滞剂仍是肥厚型梗阻性心肌病的关键治疗吗
Great Debate: beta-blockers remain a key treatment for the management of hypertrophic obstructive cardiomyopathy
β 受体阻滞剂仍是肥厚型梗阻性心肌病的关键治疗
Beta-blockers remain a key treatment for the management of hypertrophic obstructive cardiomyopathy
正方Caroline CoatsUniversity of Glasgow反方Fernando DominguezHospital Universitario Puerta De Hierro Majadahonda评论员Ahmad MasriOregon Health & Science University Medical Group
TAVI/TAVR2 场
LBCS
晚期临床科学：瓣膜性心脏病
Late-Breaking Clinical Science: valvular heart disease
EuroHeart TAVI 注册研究
EuroHeart - TAVI Registry
有症状的矛盾性低流量、低压差主动脉瓣狭窄患者中最佳药物治疗±瓣膜修复：多中心随机比较
Optimal Medical Treatment With or Without Valve Repair in Patients with symptomatic Paradoxical Low-Flow, Low-Gradient Aortic Stenosis: a multicenter, randomized comparison
球囊扩张式 TAVI 平台常规后扩张的疗效与安全性：DUOTAP 随机对照试验
Efficacy and safety of routine post-dilatation using a balloon-expandable transcatheter aortic valve implantation platform - the randomized controlled DUOTAP trial.
主动脉瓣置换术后恩格列净研究：随机临床试验
EMPagliflozin after Aortic Valve Replacement study: a randomized clinical trial
主动脉瓣狭窄经导管或外科治疗后的假体-患者不匹配：随机 DEDICATE-DZHK6 试验的亚研究
Prosthesis-Patient Mismatch after Transcatheter or Surgical Treatment of Aortic Valve Stenosis: A Sub-Study of the Randomized DEDICATE-DZHK6 Trial
LBCS
瓣膜性心脏病：真实世界实践的启示
Valvular heart disease: lessons from real-world practice
VHD-W（女性瓣膜性心脏病）研究的主要结果
Primary Results of the VHD-W (Valvular Heart Disease in Women) Study
英格兰当代 TAVI 的中期结局：全国注册研究关联数据的洞见
Medium-term outcomes following contemporary transcatheter aortic valve implantation in England: insights from national registry linkage
孤立性三尖瓣置换 20 年随访：来自最大多中心国际注册研究的洞见——DURABLE Tricuspid
Isolated Tricuspid Valve Replacement at 20-Year Follow-up. Insight from the largest multicenter international registry. DURABLE Tricuspid
三尖瓣反流减轻多少才够？随机 TRI-FR 扩展研究中 T-TEER 后的残余 TR 与长期结局
How Much Tricuspid Regurgitation Reduction Is Enough? Residual TR and Long-Term Outcomes After T-TEER in the Randomized TRI-FR Extension
二尖瓣介入（TEER）1 场
LBCS
晚期临床科学：肺动脉高压
Late-Breaking Clinical Science: pulmonary hypertension
Ralinepag 治疗改善结缔组织病相关肺动脉高压患者结局：3 期 ADVANCE Outcomes 研究结果
Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE Outcomes Study
左西孟旦治疗 HFpEF 所致肺动脉高压：LEVEL 试验结果
Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial
单张心尖四腔心超声切面自动检测肺动脉高压：基于迄今最大右心导管确诊队列开发并完成多国外部验证
Automated Detection of Pulmonary Hypertension from a Single Apical Four-Chamber Echocardiographic Clip: development on the largest RHC-confirmed cohort to date and multinational external validation
遗传性出血性毛细血管扩张症家族中的肺动脉高压：全国性家族登记研究
Pulmonary Arterial Hypertension in Families with Hereditary Hemorrhagic Telangiectasia: A Nationwide Family Registry
ARTISAN：降低后负荷改善右心室结构与功能
ARTISAN: Afterload Reduction To Improve Right Ventricular Structure And FuNction
AI 与数字技术1 场
LBCS
晚期临床科学：肺栓塞
Late-Breaking Clinical Science: pulmonary embolism
急性中危肺栓塞治疗反应的预测因素：HI-PEITHO 随机研究分析
Predictors of treatment response in acute intermediate-risk pulmonary embolism: analysis from the HI-PEITHO randomized study
中危肺栓塞的再灌注策略：荟萃分析
Reperfusion Strategies for Intermediate-Risk Pulmonary Embolism: A Meta-analysis
AI 驱动模型改进急性肺栓塞早期死亡预测：VITAL-PE 评分
An AI-driven Model to Improve Prediction of Early Mortality in Acute Pulmonary Embolism: The VITAL-PE Score
德国肺栓塞导管引导治疗的快速扩展：全国趋势与结局分析
Rapid expansion of catheter-directed therapies for pulmonary embolism in Germany: A nationwide analysis of trends and outcomes
其他1 场
Great Debates
焦点辩论：中度主动脉瓣狭窄是否应行瓣膜置换
Great Debate: aortic valve replacement for moderate aortic stenosis
中度主动脉瓣狭窄患者应行主动脉瓣置换
Patients with moderate aortic stenosis should undergo aortic valve replacement
正方Helene EltchaninoffUniversity Hospital of Rouen反方Anna Sonia PetronioPisa University Hospital评论员Marie-Annick ClavelQuebec Heart and Lung Institute
02中国专家参与场次China Faculty1 场
| 中国专家参与的报告 |
|---|
| 二尖瓣介入（TEER） · 1 项中国专家报告 |
遗传性出血性毛细血管扩张症家族中的肺动脉高压：全国性家族登记研究 Pulmonary Arterial Hypertension in Families with Hereditary Hemorrhagic Telangiectasia: A Nationwide Family Registry |
03本领域中国研究China Abstracts69 篇
| 研究标题 | 第一作者 | 所在机构 |
|---|---|---|
| 流行病学、预后与结局 · 15 篇 | ||
老年瓣膜性心脏病患者瓣膜干预的肾功能与生存获益 Renal function and survival benefit of valve intervention in elderly valvular heart disease | Yuzhe Yin | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
社会孤立、孤独、遗传易感性与蛋白质组特征与新发静脉血栓栓塞 Social isolation, loneliness, genetic predisposition and proteomic signatures, with incident venous thromboembolism | Zhanying Han | 郑州大学第一附属医院 |
COVID-19幸存者心肌损伤对一年结局的远期影响：前瞻性队列研究 Long-term effects of myocardial injury on one-year outcomes in COVID-19 survivors: a prospective cohort study | Wu He | 同济医院-同济医学院 |
特发性肺动脉高压蛋白基因组图谱揭示性别二态机制与潜在新治疗靶点 A proteogenomic atlas of idiopathic pulmonary arterial hypertension reveals sex-dimorphic mechanisms and potential novel therapeutic targets | Xinjie Lin | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
基线eGFR及其纵向轨迹对肺动脉高压临床结局的协同影响 Synergistic impact of baseline eGFR and longitudinal trajectory on clinical outcomes in pulmonary arterial hypertension | Qi Wang | 中国医学科学院北京协和医学院阜外医院 |
TAPSE/sPAP动态变化预测肺动脉高压患者长期血管反应性与预后：大型多中心回顾性研究 Dynamic changes in TAPSE/sPAP predict long-term vasoreactivity and prognosis in patients with pulmonary arterial hypertension: a large multi-center retrospective study | Yicheng Yang | 首都医科大学附属北京安贞医院 |
房颤患者单纯二尖瓣反流与单纯三尖瓣反流的临床特征与远期预后比较 Comparison of clinical characteristics and long-term prognosis between isolated mitral regurgitation and isolated tricuspid regurgitation in patients with atrial fibrillation | Kuan-Chih Huang | 台湾大学附属医院新竹分院 |
能量代谢多组学解析揭示肺动脉高压的新型因果靶点 Multi-omics interrogation of energy metabolism reveals novel causal targets in pulmonary arterial hypertension | Shiqiang Hou | 复旦大学附属中山医院 |
低复杂度先心病成人的终生非心脏共病负担与死亡风险：英国生物样本库人群队列研究 Lifelong non-cardiac comorbidity burden and mortality risk in adults with lower-complex congenital heart disease: a population-based cohort study from the UK Biobank | Jie-Xin Zhang | 北京协和医院 |
肥厚型心肌病心衰相关死亡的新型预测模型 A novel prediction model for heart failure-related death in hypertrophic cardiomyopathy | Yu Zhang | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
小左室舒张末期内径预测重度主动脉瓣狭窄TAVR术后远期全因死亡 Small left ventricular end-diastolic diameter predicts long-term all-cause mortality after TAVR in severe aortic stenosis | Can Wang | 中国医学科学院北京协和医学院阜外医院 |
性别特异性炎症蛋白组学特征预测主动脉瓣狭窄：多组学分析证据 Sex-specific inflammatory proteomic signatures predict aortic valve stenosis: evidence from multi-omics analyses | Songren Shu | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
晕厥作为急性肺栓塞高危表型的预测因子：客观临床标志物与改良sPESI评分的启示 Syncope as a predictor of high-risk phenotype in acute pulmonary embolism: insights from objective clinical markers and a modified sPESI score | Kang-Yin Chen | 天津医科大学第二医院 |
三维超声心动图评估不同病因肺动脉高压的右室-肺动脉耦联 Right ventricular-pulmonary arterial coupling in patients with different etiologies of pulmonary arterial hypertension evaluated by three-dimensional echocardiography | Haiyan Chen | 复旦大学附属中山医院 |
法布里病的室-动脉耦联与远期心血管风险 Ventricular–arterial coupling and long-term cardiovascular risk in Fabry disease | Hao Chih Chang | 台北荣民总医院 |
| 病理生理与机制 · 8 篇 | ||
胰岛素抵抗遗传易感性经单核细胞代谢重编程与免疫失调驱动肺动脉高压 Insulin resistance genetic susceptibility drives pulmonary arterial hypertension through monocyte metabolic reprogramming and immune dysregulation | Shiqiang Hou | 复旦大学附属中山医院 |
主动脉瓣间质细胞衰老图谱 Landscape of the aortic valve interstitial cell senescence atlas | Yanbing Ma | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
间质室单细胞绘图识别主动脉狭窄中SPP1相关巨噬细胞-成纤维细胞重构轴 Single-cell mapping of the interstitial compartment identifies an SPP1-associated macrophage–fibroblast remodelling axis in aortic stenosis | Guanxi Sun | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
ACKR1高表达内皮细胞增强CXCL8反应性并揭示钙化性主动脉瓣疾病的治疗切入点 ACKR1-high endothelial cells enhance CXCL8 responsiveness and reveal a therapeutic entry point in calcific aortic valve disease | Xu Nan Guo | 首都医科大学附属北京安贞医院 |
白细胞介素6在钙化性主动脉瓣疾病中的时空动态：多组学与转化研究 Spatiotemporal dynamics of interleukin 6 in calcific aortic valve disease: a multi-omics and translational study | Songren Shu | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
Hsp90α通过上调HIF-1α抑制瓣膜间质细胞成骨分化从而减轻钙化性主动脉瓣疾病 Hsp90α attenuates calcific aortic valve disease by upregulation HIF-1α and suppressing VIC osteogenesis | Yun Dai Chen | 中国人民解放军总医院 |
基底膜破坏是瓣膜性心脏病的共同发病基础：全瓣膜单细胞图谱的启示 Disruption of the basement membrane underlies common pathogenesis of valvular heart diseases revealed by a pan-valvular single-cell atlas | Hongjie Shi | 武汉大学中南医院 |
房间隔缺损相关肺动脉高压跨肺梯度代谢特征 Metabolic signatures of transpulmonary gradients in atrial septal defect associated with pulmonary arterial hypertension | Xifeng Qian | 中国医学科学院阜外医院 |
| 肥厚型心肌病 · 7 篇 | ||
玛伐凯恩对比室间隔消融：静息LVOTG≥50 mmHg的梗阻性肥厚型心肌病1年心血管事件预后差异 Mavacamten versus septal ablation: prognostic differences in 1-year cardiovascular events for HOCM with resting LVOTG ≥50 mmHg | Bi Huang | 重庆医科大学附属第一医院 |
Valsalva诱导收缩压下降作为肥厚型心肌病动态左室流出道梗阻的实时标志物 Valsalva‑induced systolic blood pressure drop as a real‑time marker of dynamic left ventricular outflow tract obstruction in hypertrophic cardiomyopathy | Ziqing yu | 中山医院 |
心肌肌球蛋白抑制剂改善肥厚型心肌病心室中部梗阻 Cardiac Myosin inhibitor improves mid-ventricular obstruction in hypertrophic cardiomyopathy | Luan Lina | 上海市老年医学中心 |
肥厚型心肌病患者左室小梁复杂度与肌节基因突变的关联 Association between left ventricular trabecular complexity and sarcomere mutation in patients with hypertrophic cardiomyopathy | Shujuan Yang | 首都医科大学附属北京安贞医院 |
室间隔切除术治疗轻度症状梗阻性肥厚型心肌病的预后分析 Prognostic analysis of septal myectomy for mildly symptomatic obstructive hypertrophic cardiomyopathy | Zhiyao Wei | 北京安贞医院 |
肥厚型心肌病心律失常风险的蛋白质组预测因子 Proteomic predictors of arrhythmic risk in hypertrophic cardiomyopathy | Yiqi Zhao | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
玛伐凯恩停药后梗阻性肥厚型心肌病的外科室间隔切除术：真实世界病例系列 Surgical myectomy after mavacamten discontinuation in obstructive hypertrophic cardiomyopathy: a real-world case series | Changrong Nie | 中国医学科学院阜外医院 |
| 肺动脉高压 · 6 篇 | ||
潜在类别分析表型先心病相关肺动脉高压：国家前瞻性注册研究的启示 Phenotyping of pulmonary arterial hypertension associated with congenital heart disease using latent class analysis: insights from a national prospective registry | Qimou Li | 中国医学科学院北京协和医学院阜外医院 |
房间隔缺损相关肺动脉高压患者克隆性造血相关基因 Clonal hematopoiesis-related genes in patients with atrial septal defect associated with pulmonary arterial hypertension | Hai-Long Dai | 昆明医科大学附属延安医院 |
先心病相关肺动脉高压患者口腔及肠道菌群特征 The characteristics of oral, and gut microbiota in patients with congenital heart disease associated with pulmonary arterial hypertension | Hai-Long Dai | 昆明医科大学附属延安医院 |
整合TAPSE/sPAP的改良四分层肺动脉高压风险评估：中国大样本真实世界队列证据 A modified 4-strata risk assessment incorporating TAPSE/sPAP for pulmonary arterial hypertension: evidence from a large chinese real-world cohort | Sicong Li | 阜外医院 |
多学科影像指导Potts分流治疗肺动脉高压：时机与风险评估 Multidisciplinary, imaging-guided Potts shunt in pulmonary hypertension: timing and risk assessment | Zhuoyuan Xu | 上海儿童医学中心 |
高强度吸气肌训练对肺动脉高压患者吸气肌力量与运动能力的影响 Effects of high-intensity inspiratory muscle training on inspiratory muscle strength and exercise capacity in pulmonary arterial hypertension | Pei-Hsi Wu | 台北荣民总医院 |
| 肺栓塞 · 3 篇 | ||
靶向PSMB9–NGAL/MMP9轴：肺动脉高压血管重构的新型中性粒细胞驱动机制与精准靶点 Targeting the PSMB9–NGAL/MMP9 Axis: a novel neutrophil-driven mechanism and precision target for vascular remodeling in PAH | Xuyu He | 广东省人民医院广东省心血管病研究所 |
症状性急性肺栓塞后患者随访峰值摄氧量的独立关联与增量预后价值 Independent associations and incremental prognostic value of follow-up peak oxygen uptake in symptomatic post-acute pulmonary embolism patients | Bei-Lan Yang | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
急性肺栓塞后持续症状患者的功能与血流动力学异质性 Functional and haemodynamic heterogeneity of post-acute pulmonary embolism patients with persistent symptoms | Bei-Lan Yang | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
| 介入治疗 · 3 篇 | ||
穴位经皮电刺激对心脏手术后早期自主神经功能的影响：随机对照试验 Effect of acupoint transcutaneous electrical nerve stimulation on early postoperative autonomic function after cardiac surgery: a randomised controlled trial | Zeruxin Luo | 四川大学华西医院 |
04企业卫星会Industry Symposia35 个系列
赞助商分布12 场 · Pfizer 6 场 · Siemens Healthineers 5 场 · Cytokinetics 5 场 · Bayer AG 4 场 · Philips 3 场 · Bristol-Myers Squibb 3 场 · Alnylam Pharmaceuticals 2 场 · Medcon International 2 场 · Abbott 1 场 · Penumbra
心肌病与心包12 个系列
Cytokinetics
加速照护：aficamten 用于梗阻性肥厚型心肌病的临床实践（系列共 4 场）
Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten
加速诊疗：临床实践中用 aficamten 管理梗阻性肥厚型心肌病
Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten
Lexeo
重新定义 Friedreich 共济失调心肌病的预后判断：左心室质量指数与 AI 洞察
Redefining prognostication in Friedreich ataxia cardiomyopathy: the role of left ventricular mass index and artificial intelligence-enabled insights
重新定义弗里德赖希共济失调心肌病的预后评估：左心室质量指数与人工智能洞察的作用
Redefining prognostication in Friedreich ataxia cardiomyopathy: the role of left ventricular mass index and artificial intelligence-enabled insights
BridgeBio
时机至关重要：ATTR-CM 的 AI 筛查新方法与治疗时机的临床考量
Time matters in transthyretin amyloid cardiomyopathy (ATTR-CM): emerging artificial intelligence approaches to screening and clinical considerations for treatment timing
开幕致辞与 ATTR-CM 介绍
Opening address and introduction to ATTR-CM
及时检测 ATTR-CM 的重要性
Importance of timely detection of ATTR-CM
ATTR-CM 筛查的新兴 AI 方法
Emerging artificial intelligence approaches to ATTR-CM screening
TTR 稳定剂治疗 ATTR-CM 时机的临床考量
Clinical considerations for ATTR-CM treatment timing with a TTR stabiliser
ATTR-CM 中时间至关重要：新兴 AI 筛查方法与治疗时机临床考量——讨论与闭幕
Time matters in ATTR-CM: emerging artificial intelligence approaches to screening and clinical considerations for treatment timing - discussion and closing
Bristol-Myers Squibb
肥厚型心肌病峰会：提升梗阻性 HCM 诊断水平与真实世界证据
Hypertrophic cardiomyopathy summit: elevating diagnosis and emerging real-world evidence in obstructive hypertrophic cardiomyopathy
欢迎与介绍
Welcome and introduction
提升梗阻性肥厚型心肌病的诊断水平
Elevating diagnosis in obstructive hypertrophic cardiomyopathy
mavacamten 对心脏结构与功能的影响
Impact of mavacamten on cardiac structure and function
马瓦卡姆腾的真实世界证据与结局
Real-world evidence and outcomes with mavacamten
肥厚型心肌病峰会：提升梗阻性肥厚型心肌病诊断与新兴真实世界证据——讨论与问答
Hypertrophic cardiomyopathy summit: elevating diagnosis and emerging real-world evidence in obstructive hypertrophic cardiomyopathy - discussion and Q&A
Bayer AG
临床病例大师课：解析心衰实践中 ATTR-CM 的疑难表现
Clinical cases masterclass: decoding challenging transthyretin amyloid cardiomyopathy presentations in heart failure clinical practice
临床病例大师课：解读心衰临床实践中具有挑战性的转甲状腺素蛋白淀粉样心肌病表现
Clinical cases masterclass: decoding challenging transthyretin amyloid cardiomyopathy presentations in heart failure clinical practice
Medcon International
推动梗阻性 HCM 进展：心肌肌球蛋白抑制剂时代
Moving the needle in obstructive hypertrophic cardiomyopathy: the era of cardiac myosin inhibitors
欢迎致辞
Welcome
2026 年找到合适的梗阻性肥厚型心肌病患者：当静息数据不够用时
Finding the right obstructive hypertrophic cardiomyopathy patient in 2026: when resting data are not enough
从认识到行动：不断演进的心肌肌球蛋白抑制剂证据对实践的意义
From recognition to action: what the evolving cardiac myosin inhibitors evidence means for practice
学以致用：基于病例的应用与听众投票
Let’s apply what you’ve learned: case-based application with audience voting
推动梗阻性肥厚型心肌病的改变：心肌肌球蛋白抑制剂时代——要点回顾与问答
Moving the needle in obstructive hypertrophic cardiomyopathy: the era of cardiac myosin inhibitors - Key takeaways and Q&A
Alnylam Pharmaceuticals
聚焦：ATTR-CM 管理的下一个时代
In focus: the next era of transthyretin amyloid cardiomyopathy (ATTR-CM) management
欢迎与介绍
Welcome and introductions
专家视角：不断演进的 ATTR-CM 格局
Expert perspectives on the evolving ATTR-CM landscape
解读 ATTR-CM 临床试验设计
Contextualising ATTR-CM clinical trial designs
基于证据的 ATTR-CM 临床诊疗
Evidence-based ATTR-CM care in practice
问答与闭幕
Q&A and closing
Bayer AG
临床病例大师课：识别与应对 ATTR-CM 疾病进展
Clinical cases masterclass: Recognising and responding to disease progression in transthyretin amyloid cardiomyopathy
临床病例大师课：识别并应对转甲状腺素蛋白淀粉样心肌病的疾病进展
Clinical cases masterclass: Recognising and responding to disease progression in transthyretin amyloid cardiomyopathy
Bristol-Myers Squibb
从检出到临床获益：梗阻性肥厚型心肌病的诊断优化与真实世界管理（系列共 2 场）
From detection to clinical impact: optimising diagnosis and real-world management of obstructive hypertrophic cardiomyopathy
从检测到临床影响：优化梗阻性肥厚型心肌病的诊断与真实世界管理
From detection to clinical impact: optimising diagnosis and real-world management of obstructive hypertrophic cardiomyopathy
Pfizer
重审 ATTR-CM：仍然重要的问题
Reframing transthyretin amyloid cardiomyopathy (ATTR-CM): the questions that still matter
欢迎与介绍
Welcome and introduction
ATTR-CM 从怀疑走向确诊：我们需要挑战诊断假设吗？
Moving from suspicion to confirmation in ATTR-CM: do we need to challenge our diagnostic assumptions?
解读 TTR 动态变化：它们究竟告诉我们什么？
Interpreting TTR dynamics: what do they really tell us?
ATTR-CM 的优化纵向诊疗在临床实践中是什么样的？
What does optimal longitudinal care in ATTR-CM look like in clinical practice?
重新审视转甲状腺素蛋白淀粉样心肌病（ATTR-CM）：仍至关重要的问题——讨论与问答
Reframing transthyretin amyloid cardiomyopathy (ATTR-CM): the questions that still matter - Discussion and Q&A
Medcon International
从证据到实践：肌球蛋白抑制剂贯穿肥厚型心肌病全程
Translating evidence into practice: myosin inhibition across the hypertrophic cardiomyopathy spectrum
欢迎致辞
Welcome
将机制洞察转化为临床决策
Translating mechanistic insights into clinical decision-making
从实验室到临床：梗阻性肥厚型心肌病患者的以患者为中心的照护与共享决策
From bench to bedside: patient-centred care and shared decision-making in patients with obstructive hypertrophic cardiomyopathy
非梗阻性肥厚型心肌病：地平线上有什么？
Non-obstructive hypertrophic cardiomyopathy: what’s on the horizon?
将证据转化为实践：肌球蛋白抑制在肥厚型心肌病谱系中的应用——专家讨论与问答
Translating evidence into practice: myosin inhibition across the hypertrophic cardiomyopathy spectrum - Panel discussion and Q&A
Intellia
直击源头：体内 CRISPR 基因编辑治疗 ATTR-CM
Targeting the source: in vivo CRISPR-based gene editing for transthyretin amyloid cardiomyopathy (ATTR-CM)
欢迎与介绍
Welcome and introduction
ATTR 淀粉样变患者诊疗的复杂性
Complexities of patient care in ATTR amyloidosis
CRISPR 基因编辑在心脏病学中的应用价值
The utility of CRISPR gene editing in cardiology
探索 ATTR-CM 中的 CRISPR 基因编辑
Exploring CRISPR-based gene editing in ATTR-CM
靶向根源：体内 CRISPR 基因编辑治疗 ATTR-CM——听众问答
Targeting the source: in vivo CRISPR-based gene editing for ATTR-CM - Q&A from the audience
二尖瓣介入（TEER）4 个系列
Siemens Healthineers
二尖瓣影像：筛查与治疗（系列共 2 场）
Imaging the mitral valve: screening and treatment
二尖瓣成像：筛查与治疗
Imaging the mitral valve: screening and treatment
Philips
原发性还是继发性：破解二尖瓣反流的病因密码
Primary or secondary? Cracking the mitral regurgitation code
原发性还是继发性？破解二尖瓣反流之谜
Primary or secondary? Cracking the mitral regurgitation code
Philips
修复、置换还是夹合：原发性二尖瓣反流治疗选择
Fix, replace, or clip? Treating primary mitral regurgitation
修复、置换还是夹闭？原发性二尖瓣反流的治疗
Fix, replace, or clip? Treating primary mitral regurgitation
Philips
当药物治疗不够时：继发性二尖瓣反流的经导管缘对缘修复
When medical therapy is not enough — Transcatheter edge-to-edge repair for secondary mitral regurgitation
当药物治疗不足时——经导管缘对缘修复治疗继发性二尖瓣反流
When medical therapy is not enough — Transcatheter edge-to-edge repair for secondary mitral regurgitation
三尖瓣介入3 个系列
Philips
转诊谁、为何转诊：三尖瓣反流的危险信号
Who to refer and why — Red flags in tricuspid regurgitation
转诊对象与原因——三尖瓣反流中的警示信号
Who to refer and why — Red flags in tricuspid regurgitation
Siemens Healthineers
三尖瓣反流中的右心室影像：自动化与高级超声实践（系列共 3 场）
Imaging the right ventricle in tricuspid regurgitation: automation and advanced echocardiography in practice
三尖瓣反流中的右心室成像：自动化与先进超声心动图实践
Imaging the right ventricle in tricuspid regurgitation: automation and advanced echocardiography in practice
Siemens Healthineers
三尖瓣影像：筛查与治疗
Imaging the tricuspid valve: screening and treatment
三尖瓣成像：筛查与治疗
Imaging the tricuspid valve: screening and treatment
女性与性别差异2 个系列
Pfizer
从漏诊到识别：关注女性 ATTR-CM（系列共 2 场）
From missed to recognised | Bringing ATTR-CM into focus in women
从被忽视到被认识：让女性 ATTR-CM 走进视野
From missed to recognised | Bringing ATTR-CM into focus in women
Pfizer
同病不同面：女性 ATTR-CM 的临床差异（系列共 2 场）
Same disease, different faces | Clinical differences in women with ATTR-CM
同病不同貌 | 女性 ATTR-CM 患者的临床差异
Same disease, different faces | Clinical differences in women with ATTR-CM
肺动脉高压与 PADN1 个系列
MSD
激活素信号抑制剂在肺动脉高压中的结局解读
Contextualising outcomes behind activin signaling inhibitor in pulmonary arterial hypertension
激活素信号抑制剂对后负荷、右室功能与结构的影响：三重角度
Effects of activin signaling inhibitor on afterload, right ventricular function, and structure: a 3-prong view
解析激活素信号抑制剂改善肺动脉高压运动能力的中枢、外周与血液学获益机制
Disentangling the central, peripheral, and haematological mechanisms of benefit of activin signaling inhibitor on exercise performance in pulmonary arterial hypertension
肺动脉高压风险评估中的血流动力学参数：心输出量重要吗？
Haemodynamic parameters as part of risk assessment in pulmonary arterial hypertension: does cardiac output matter?
激活素信号抑制剂：从临床结局到生理学理解
Activin signaling inhibitor: from clinical outcomes to physiologic understanding
解读肺动脉高压中激活素信号抑制剂背后的结局——讨论与问答
Contextualising outcomes behind activin signaling inhibitor in pulmonary arterial hypertension - discussion and Q&A
综合与其他13 个系列
Penumbra
应对肺栓塞的复杂性：从危险分层到高级治疗
Navigating complexity in pulmonary embolism: from risk stratification to advanced therapies
为什么肺栓塞需要新的治疗选择？
Why do we need new treatment options in pulmonary embolism?
中高危肺栓塞：何时干预最合适？
Intermediate-high risk pulmonary embolism: when is the right time to intervene?
高危肺栓塞：所有患者都一样吗？
High risk pulmonary embolism: are all patients the same?
计算机辅助真空血栓抽吸：证据与新兴数据
Computer assisted vacuum thrombectomy: evidence and emerging data
应对肺栓塞的复杂性：从危险分层到先进疗法——讨论与闭幕致辞
Navigating complexity in pulmonary embolism: from risk stratification to advanced therapies - discussion and closing remarks
Bayer AG
今昔对比：ATTR-CM 照护的变迁与思考
Then and now: reflections on the transformation of ATTR-CM care
引言
Introduction
优化治疗决策：为何 ATTR-CM 中起效速度很重要
Optimising treatment decisions: why speed of effect matters in ATTR-CM
优化治疗决策：ATTR-CM 中效应强度的临床意义
Optimising treatment decisions: the clinical relevance of strength of effect in ATTR-CM
优化治疗决策：真实世界中个体化 ATTR-CM 治疗
Optimising treatment decisions: personalising ATTR-CM treatment in real-world practice
闭幕致辞
Closing remarks
Alnylam Pharmaceuticals
理解厚心脏：诊断路径与治疗机制
Understanding thick hearts: diagnostic pathways and therapeutic mechanisms
欢迎与介绍
Welcome and introduction
厚壁心脏的临床背景与诊断考量
Clinical context of thick hearts and diagnostic considerations
ATTR 的病理生理与基于机制的疗法
Pathophysiology of ATTR and mechanism-based therapeutics
vutrisiran 治疗转甲状腺素蛋白心肌病的临床证据
Clinical evidence for vutrisiran in transthyretin cardiomyopathy
理解厚壁心脏：诊断路径与治疗机制——讨论与问答
Understanding thick hearts: diagnostic pathways and therapeutic mechanisms - discussion and Q&A
Pfizer
全貌：优化 ATTR-CM 的整体监测与管理（系列共 3 场）
The complete picture | Optimising holistic monitoring and management of ATTR-CM
完整图景 | 优化 ATTR-CM 的整体监测与管理
The complete picture | Optimising holistic monitoring and management of ATTR-CM
Bayer AG
临床病例大师课：ATTR-CM 的诊断复杂性与治疗决策
Clinical cases masterclass: navigating diagnostic complexity and treatment decisions in ATTR-CM
临床病例大师课：ATTR-CM 诊断复杂性与治疗决策导航
Clinical cases masterclass: navigating diagnostic complexity and treatment decisions in ATTR-CM
Pfizer
将最新证据转化为临床实践，改善 ATTR-CM 结局
Translating recent evidence into clinical practice for improved outcomes in ATTR-CM
欢迎与介绍
Welcome and introduction
深入探讨 ATTR-CM 的病理生理与治疗方法
Taking a closer look at ATTR-CM pathophysiology and therapeutic approaches
长期数据如何指导 ATTR-CM 的真实世界决策？
How do long-term data inform real-world decisions in ATTR-CM?
超越治疗启动：为 ATTR-CM 提供整体化长期照护
Beyond treatment initiation: delivering holistic, long-term care in ATTR-CM
专家讨论
Panel discussion
将最新证据转化为临床实践以改善 ATTR-CM 结局——问答
Translating recent evidence into clinical practice for improved outcomes in ATTR-CM - Q&A
Medtronic
从诊断到远期结局：心脏团队主导的主动脉瓣狭窄管理
From diagnosis to long term outcomes: a practical heart team approach to aortic stenosis management
主动脉瓣狭窄的实用诊断：心脏团队需要了解的内容
Practical diagnosis of aortic stenosis: what the heart team needs to know
优化患者路径：从诊断到治疗决策
Optimising the patient pathway: from diagnosis to treatment decision
治疗后的影像学检查：随访为何重要
Post‑treatment imaging: why follow‑up matters
Pfizer
伟大的伪装：在临床实践中更早识别 ATTR-CM（系列共 3 场）
The great masquerade | Unmasking ATTR-CM earlier in clinical practice
伟大的伪装者 | 在临床实践中更早揭露 ATTR-CM
The great masquerade | Unmasking ATTR-CM earlier in clinical practice
Abbott
超声现场演示：诊断、筛查并转诊至经导管缘对缘修复（系列共 2 场）
Live echocardiography | Diagnose, screen and refer your patients to transcatheter edge-to- edge repair
现场超声心动图｜诊断、筛查并将患者转诊至经导管缘对缘修复
Live echocardiography | Diagnose, screen and refer your patients to transcatheter edge-to- edge repair
Bayer AG
转甲状腺素蛋白淀粉样变心肌病：重新定义风险以优化患者结局
ATTR-CM: redefining risk to optimise patient outcomes
引言
Introduction
ATTR-CM：理解患者负担与风险加速
ATTR-CM: understanding patient burden and risk acceleration
改变轨迹：降低风险的干预措施
Changing the trajectory: interventions to mitigate risk
应对残余风险：识别并预防疾病进展
Responding to residual risk: identifying and preventing disease progression
闭幕致辞
Closing remarks
Cytokinetics
梗阻性肥厚型心肌病治疗进展与 aficamten 临床实践
Advancements in treatment for oHCM and clinical practice experiences with aficamten
梗阻性肥厚型心肌病与阿非卡姆腾在临床中不断演变的格局
The evolving landscape of oHCM and aficamten in the clinical setting
阿非卡姆腾在欧洲的实践经验与考量
Practical experience and considerations with aficamten in Europe
美国 aficamten 临床应用经验
Clinical experience with aficamten from the US
oHCM 治疗进展与 aficamten 临床实践体验——要点回顾与讨论
Advancements in treatment for oHCM and clinical practice experiences with aficamten - Key takeaways and discussion
Inari
肺栓塞管理进阶：从新证据到及时干预
Advancing pulmonary embolism management: from emerging evidence to timely intervention
急性肺栓塞的新兴证据：来自临床试验与真实世界数据的经验
Evolving evidence in acute pulmonary embolism: learnings from clinical trials and real-world data
急性肺栓塞何时应在抗凝基础上升级治疗：谁是适合介入的患者
When should we escalate beyond anticoagulation in acute pulmonary embolism: who is a right patient for intervention
大腔机械血栓抽吸治疗急性肺栓塞：实践经验与病例心得
Large-bore mechanical thrombectomy in acute pulmonary embolism: practical experience and case learnings
推进肺栓塞管理：从新兴证据到及时干预——问答
Advancing pulmonary embolism management: from emerging evidence to timely intervention - Q&A
Alnylam Pharmaceuticals
证据与经验交汇：重新定义 ATTR-CM 的治疗预期
Where evidence meets experience: redefining ATTR-CM treatment expectations
超越当前诊疗：ATTR-CM 未被满足的需求
Looking beyond current care: the unmet need in ATTR-CM
构建证据基础：ATTR-CM 的一线治疗选择
Building the evidence base: a first-line therapy option in ATTR-CM
扩展的数据与临床洞见：驱动治疗决策
Expanded data and clinical insights: driving treatment decisions
证据与经验交汇：重新定义 ATTR-CM 治疗预期——听众讨论与问答
Where evidence meets experience: redefining ATTR-CM treatment expectations - Discussion and Q&A from the audience
企业卫星会内容由赞助方支持，此处仅作学术日程信息陈列，不代表编辑立场。